The Patent Finder

Terms ending in 2034

2SEVENTY Bio, Inc.

Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,000,746A Laglidadg Homing Endonuclease Cleaving the T Cell Receptor Alpha Gene and Uses Thereof
In force
 · High confidence
2SEVENTY Bio, Inc.In forceHigh confidence
US 10,006,052A Laglidadg Homing Endonuclease Cleaving the C-C Chemokine Receptor TYPE-5 (CCR5) Gene and Uses Thereof
In force
 · High confidence
2SEVENTY Bio, Inc.In forceHigh confidence
US 10,196,444Multipartite Signaling Proteins and Uses Thereof
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 10,428,142Multipartite Signaling Proteins and Uses Thereof
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 10,457,731Multipartite Signaling Proteins and Uses Thereof
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited